British Society of Gastroenterology
Guideline
Jun 2025
For professionals
The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.
Topics
About Crohn's disease
Diagnosis and tests
Medicines
Monitoring
Complications
Surgery
Jargon explained
Montreal classification
remission
endoscopic remission
inflammatory bowel disease
advanced therapy
GRADE
induction
maintenance
European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
American Gastroenterological Association (Gastroenterology)
Guideline
Jun 2021
For professionals
The American Gastroenterological Association's guideline on medicines for moderate to severe Crohn's, including fistulas around the anus. It rates the strength of evidence behind each drug option. It is American, so some drug choices and approvals differ from the NHS, but it is free to read in full and widely cited.
Topics
Medicines
Biologics and newer medicines
Around the bottom (perianal)
Jargon explained
luminal
perianal fistulizing
certainty of evidence
Cochrane
Systematic review
May 2025
Patients and professionals
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics
Biologics and newer medicines
Jargon explained
IL-12/23
induction
certainty of evidence
ECCO
Web page
2024
For professionals
ECCO's own account of how its 2024 Crohn's treatment guidelines were produced: four working groups of international experts, including an IBD nurse, a dietitian and patient representatives, supported by methodologists.
Topics
Medicines
Surgery
Jargon explained
GRADE
working group
patient representatives
Cochrane
Systematic review
Jul 2023
Patients and professionals
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics
Biologics and newer medicines
Research
Jargon explained
high-certainty evidence
induction
maintenance
integrin
Cochrane
Systematic review
Jul 2020
Patients and professionals
Cochrane found only two small trials of probiotics ('good bacteria' supplements) for active Crohn's. The evidence is very uncertain, so we do not know whether probiotics help or are safe for this purpose.
Topics
Diet and nutrition
Medicines
Jargon explained
probiotic
very low certainty evidence
Cochrane (via PMC)
Systematic review
Nov 2019
Patients and professionals
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
Topics
Biologics and newer medicines
Research
Jargon explained
induction
placebo
anti-TNF
Cochrane
Systematic review
Apr 2020
Patients and professionals
Fatigue is one of the most common complaints in IBD, but this review found too little good-quality research to say which treatments help. The authors call for bigger studies that measure fatigue as the main outcome.
Topics
Fatigue
Research
Jargon explained
fatigue
low certainty evidence
systematic review
cognitive behavioural therapy
Cochrane
Systematic review
Aug 2019
Patients and professionals
Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.
Topics
Immunosuppressants
Surgery
Research
Jargon explained
postoperative recurrence
low certainty evidence
post-operative recurrence
thiopurine
5-ASA
anti-TNF
Cochrane
Systematic review
Oct 2015
Patients and professionals
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics
Immunosuppressants
Research
Jargon explained
thiopurine
low-quality evidence
adverse event
remission
placebo
systematic review
Cochrane (via PMC)
Systematic review
Aug 2014
Patients and professionals
A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.
Topics
Immunosuppressants
Research
Jargon explained
methotrexate
intramuscular
maintenance